Y-mAbs started at Outperform by Wedbush

Target $58

https://www.benzinga.com/stock/YMAB/ratings

Spero started at Buy by Wainwright

Target $28

https://www.benzinga.com/stock/SPRO/ratings

Replimune started at Buy by Roth

Target $20

https://www.benzinga.com/stock/REPL/ratings

Dr Reddy’s upped to Outperform from Underperform by Credit Suisse

https://www.benzinga.com/stock/RDY/ratings

Ovid Therapeutics started at Outperform by RBC

Target $12

https://www.benzinga.com/stock/OVID/ratings

Intercept upgraded to Buy from Neutral by Citi

Target to $85 from $106

https://www.benzinga.com/stock/ICPT/ratings

Emergent BioSolutions upped to Outperform by Wells Fargo

From Market Perform; target to $64 from $61

https://www.benzinga.com/stock/EBS/ratings